Envestnet Asset Management
LAB icon

Envestnet Asset Management’s Standard BioTools LAB Stock Holding History

Envestnet Asset Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-10,116
Closed -$10.9K – 4510
2025
Q1 		$10.9K Buy
+10,116
New +$14.2K ﹤0.01% 4332
2024
Q4 		– Sell
-10,571
Closed -$20.4K – 4350
2024
Q3 		$20.4K Buy
10,571
+546
+5% +$1.07K ﹤0.01% 4201
2024
Q2 		$17.7K Buy
+10,025
New +$24.5K ﹤0.01% 4143

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Envestnet Asset Management's LAB Position: Q2 2025 in Review

Envestnet Asset Management sold out of Standard BioTools (LAB) in Q2 2025, closing a stake of 10,116 shares — an estimated $10.9K sold.

Envestnet Asset Management first reported a position in LAB in Q2 2024 and held it in 3 quarters. The position peaked at $20.4K in Q3 2024. 160 funds tracked by Wall St. Rank hold LAB as of Q2 2025.

  • Envestnet Asset Management reported no remaining Standard BioTools position as of Q2 2025 after selling out during the quarter.
  • Envestnet Asset Management sold 10,116 Standard BioTools shares in Q2 2025, an estimated $10.9K.
  • Envestnet Asset Management first reported a position in Standard BioTools in Q2 2024 and held it in 3 quarters.
  • Envestnet Asset Management's Standard BioTools position peaked at $20.4K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2025.

Based on Envestnet Asset Management's 13F filing for Q2 2025, filed 1 Aug 2025.